Trials / Completed
CompletedNCT00555061
Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 2 Months – 24 Months
- Healthy volunteers
- Not accepted
Summary
A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retapamulin Ointment, 1% | 1% Ointment |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-08-01
- Completion
- 2008-08-01
- First posted
- 2007-11-07
- Last updated
- 2016-12-28
- Results posted
- 2010-04-30
Locations
25 sites across 9 countries: United States, Argentina, Chile, Costa Rica, Germany, Mexico, Netherlands, South Africa, Taiwan
Source: ClinicalTrials.gov record NCT00555061. Inclusion in this directory is not an endorsement.